Table 1. Clinical characteristics and laboratory findings in patients with ZNF384 gene rearrangements.

UPN.NO	Age/ Sex	Total WBC (/cu.mm)	Blast (%)	CD10 (%)	CD13 (%)	CD33 (%)	Karyotype	Fusion partner (RT-PCR)	End Induction MRD
FS 39/19	59/M	16 900	94	37.7	66.4	93.1	46,XY,t(12;17)(p13.3;q11.2) [16]/ 47,idem,+8[4]	TAF15	Positive (0.202%)
FS 42/19	33/M	6200	29	34.1	61.6	85	46,XY,add(7)(p11.1),del(7) (p11.1)[12]/46,XY[8]	TCF3 FISH only	aNot applicable
FS 52/19	23/M	34 000	88	47.6	60.4	15	46,XY[20]	EP300	Positive (0.411%)
FS 84/19	13/F	11 100	56	58	1.7	91.1	46,XX,del(7)(q22)[9]/ 46,XX[11]	EP300	Positive (1.735%)
FS 62/19	2/M	10 100	79	44.1	13.5	84.4	46,XY[20]	EP300-FISH only	aNot applicable
F1002/19	9/F	18 600	83	11.8	94.8	97.1	46,XX[20]	EP300	Positive (0.500%)
FS124/19	2/M	45 700	73	55.2	73.9	17.5	46,XY[22]	EP300	Negative
FS04/20	25/M	12 100	39	1.7	21.9	86.7	46 ~ 47,XY,del(1)(q32),?der (16), add(17)(q25), -20,+mar, +mar [cp7]/ 46,XY[19]	EP300	Positive (2.247%)
FS113/20	48/M	3200	96	17.9	90.4	80.4	46,XY,t(2;5)(p12;q35), del(13) (q13q32)[15]/ 46,XY[5]	EP300	Negative
FS124/20	22/M	5400	61	43.1	44.5	84.6	46,XY[20]	EP300	Negative
FS125/20	52/M	2000	90	7.5	42.3	83.9	46,XY,add(20)(q13.3) [2]/ 46,XY[18]	EP300-FISH only	Not available
FS127/20	20/F	5500	92	56.9	6.9	70.9	46,XX,ins(5;13) (q31;q13q33) [11]/ 46,XX[9]	EP300	aNot applicable
FS162/20	41/F	9100	82	0.3	46.8	86.4	46,XX[21]	EP300	Positive (0.463%)
FL 54/20	33/M	16 900	97	14	52.2	51	47,XY,+X[11]/48,idem, +12[4]/46,XY[6]	EP300-FISH only	aNot applicable

Note: Abbreviations: CD, Cluster of differentiation; MRD, Measurable residual disease; RT-PCR, Reverse transcriptase-polymerase chain reaction; WBC, White blood cell.

^aPatients who discontinued treatment at the study center.